TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Down 45.5% in November

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) was the recipient of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 31,800 shares, a decrease of 45.5% from the October 31st total of 58,400 shares. Based on an average daily volume of 44,200 shares, the short-interest ratio is currently 0.7 days. Currently, 0.7% of the shares of the stock are sold short.

TriSalus Life Sciences Stock Down 1.6 %

Shares of NASDAQ TLSI traded down $0.07 on Thursday, hitting $4.25. The company had a trading volume of 234,458 shares, compared to its average volume of 39,429. The business has a 50 day moving average of $4.23 and a two-hundred day moving average of $5.48. The firm has a market capitalization of $129.58 million, a P/E ratio of -1.71 and a beta of 0.49. TriSalus Life Sciences has a 12-month low of $3.61 and a 12-month high of $10.42.

Wall Street Analysts Forecast Growth

TLSI has been the subject of a number of recent analyst reports. Oppenheimer initiated coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target for the company. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Northland Securities assumed coverage on TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective on the stock. Canaccord Genuity Group cut their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $12.08.

Insider Buying and Selling

In related news, CEO Mary T. Szela bought 7,520 shares of the stock in a transaction dated Thursday, September 12th. The shares were acquired at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the acquisition, the chief executive officer now directly owns 377,382 shares in the company, valued at approximately $1,962,386.40. This trade represents a 2.03 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders purchased a total of 19,560 shares of company stock worth $95,190 in the last 90 days. Insiders own 32.80% of the company’s stock.

Institutional Investors Weigh In On TriSalus Life Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Highbridge Capital Management LLC bought a new position in TriSalus Life Sciences in the second quarter worth about $1,184,000. Duquesne Family Office LLC lifted its holdings in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares during the period. Geode Capital Management LLC grew its stake in shares of TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after purchasing an additional 62,542 shares during the last quarter. Wolverine Asset Management LLC acquired a new position in TriSalus Life Sciences in the second quarter worth approximately $240,000. Finally, MSD Partners L.P. acquired a new stake in shares of TriSalus Life Sciences during the third quarter worth $184,000. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.